All News

Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.

Post hoc analysis of the NAPOLI 3 trial suggests that proactively managing NALIRIFOX-induced diarrhea could allow patients with PDAC to remain on treatment longer.

Race, education, and arm pain were found to influence acupuncture expectancy in patients who are survivors of breast cancer.

Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.

An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

The developer will conduct a US feasibility test to evaluate the safety and efficacy of the SIRA RFA Electrosurgical Device in patients who require breast-conservation surgery.

Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.

The Integrated Palliative Care Outcome Scale showed the potential to guide palliative care integration to better help patients and clinicians after AHSCT.

Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.

“Psycho-oncology has made remarkable progress; however, there are still critical areas for further development,” Cristiane D. Bergerot, PhD, BS, MS, said.

A total of 32% of registered nurses and 29% of infusion nurses reported that educating patients regarding their diseases was challenging.

The study found that older females with central nervous system tumors had significantly lower vigorous physical activity participation vs their counterparts.

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data.

Real-world data may support a new way to consider follow-up treatment for patients who are older with extensive-stage small cell lung cancer.

Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.

Postoperative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.

Investigators will assess the safety, pharmacology, and maximum tolerated dose of ST-001 in relapsed/refractory SCLC as part of a phase 1a/1b trial.

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

The International Psycho-Oncology Society announced the first-ever WPOD on April 9, 2025, to bring more focus to psychosocial care in cancer therapy.

It is crucial that oncologists and other cancer care specialists collaborate with psycho-oncology specialists to optimize patient treatment outcomes.

World Psycho-Oncology Day is an initiative aimed at spreading awareness and pursuing the further integration of psychosocial care into cancer treatment.

Organizations such as ASCO and ESMO recognize the importance of integrating psychosocial care into cancer treatment.

Combining durvalumab with chemotherapy produced a good safety profile without increasing surgical risk in the phase 2 iNDUCT-GETUG V08 trial.

A phase 2 study found that treatment with tumor-infiltrating lymphocytes elicited a partial response rate of 15.1% in patients with gastrointestinal cancers.

The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.

Palbociclib with endocrine therapy did not improve outcomes in hormone receptor–positive, HER2-negative breast cancer but improved invasive DFS in lobular disease.